Business Context and Reporting Period
This Form 8-K Current Report was filed by Establishment Labs Holdings Inc. on July 13, 2021. The filing reports on corporate governance changes effective immediately on the date of the report.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on personnel appointments and equity compensation.
Material Changes
- Board Appointments: The Board appointed Ms. Ann Custin and Mr. Bryan Slotkin as Class III directors, with terms expiring in 2024.
- Committee Assignments: Ms. Custin was appointed to the Audit and Compensation Committees. Mr. Slotkin was appointed to the Audit and Nominating and Corporate Governance Committees.
- Financial Expert Qualification: Both appointees were determined to qualify as Audit Committee Financial Experts based on their prior experience.
- Equity Compensation: Each new director was granted a stock option for 12,000 Common Shares. The options vest one-third on July 13, 2022, and annually thereafter, contingent on continued service.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to the rationale for the appointments, citing Ms. Custin's expertise in medical device companies and Mr. Slotkin's experience advising public company boards.
Investor Verification Checklist
- Verify the vesting schedule and terms of the 12,000 share options granted to Ms. Custin and Mr. Slotkin under the 2018 Equity Incentive Plan.
- Confirm the updated composition of the Audit, Compensation, and Nominating and Corporate Governance Committees.
- Review the attached Press Release (Exhibit 99.1) for additional context on the appointments.
- Check the Definitive Proxy Statement filed on April 14, 2021, for details on the standard non-employee director compensation program.